Caca-Diamond Elemene Science and Technology Progress Award Fund
On April 6, 2009, with the approval of the Sixth Executive Meeting of the Sixth China Anti-Cancer Association, the Science and Technology Award Leading Group and the Science and Technology Award Office of the China Anti-Cancer Association were established and officially launched in May 2009.
At present, the Articles of Association for Science and Technology Awards of China Anti-Cancer Association and the Measures for Science and Technology Awards of China Anti-Cancer Association have been published on the website of China Anti-Cancer Association. At the same time, the Notice on Recommending Experts of Science and Technology Award of China Anti-Cancer Association and the Notice on Recommending Science and Technology Award of China Anti-Cancer Association in 2009 were issued to relevant recommendation departments throughout the country.
The purpose of the Science and Technology Award of China Anti-Cancer Association is to reward the oncology medical workers and units in China who have made outstanding contributions to the progress of oncology science and technology. The Science and Technology Award of the Association is planned to be divided into three grades: the first prize is 50,000 yuan; The second prize is 30,000 yuan; Third prize 1000 yuan. The total number of incentive projects is planned to be 30.
Elemene Oncology Postgraduate Scholarship Fund
In order to actively encourage young students to study for graduate students majoring in clinical oncology in China, carry out in-depth clinical and applied basic research, and vigorously promote the cultivation and construction of clinical oncology talents in China, CSCO Society and Dalian Huali Jingang Pharmaceutical Co., Ltd. sincerely cooperated to jointly establish the "CSCO- Jingang Elemene Oncology Postgraduate Scholarship Fund" to select some clinical oncology graduate students with excellent academic performance for scholarship support. Through consultation, both parties have formulated specific management measures as follows:
First, the basic situation of the funded object
1. Affiliated hospitals of domestic universities, national or provincial cancer research institutes, provincial cancer hospitals and tertiary hospitals are studying for master's degree, doctor's degree and postdoctoral degree in clinical oncology.
2. Applicants for postgraduate scholarships must be well-behaved, honest and decent, law-abiding, study hard, work hard, love their majors and have excellent results.
3. In addition to the above conditions, the applicant for postgraduate funding must also be a person with special financial difficulties in his family and himself.
Two. Application procedure of the fund
1. Postgraduates who meet the requirements of the fund apply to the CSCO office or download the CSCO-adamantane Oncology Postgraduate Scholarship Fund Application Form from the CSCO website.
2. The applicant shall fill in the application form truthfully as required, and provide materials such as study and research background and subject introduction. Among them, those who apply for postgraduate funding must also provide proof of financial difficulties issued by the school or the civil affairs department.
3. June 30th of each year is the deadline for application for this year's fund.
Three. Approval of the fund
1. The main procedures include formal review and Committee approval, which are reviewed once a year.
2.CSCO office is responsible for formal review, including whether the applicant meets the basic conditions of fund support and the integrity review of the application form and related procedures.
3. After the formal review, according to the fund management measures, the review committee will conduct an open, fair and equitable review of the applicant and its projects.
4. The CSCO office will inform the applicant of the evaluation results in written form, and the personnel and projects that have won the postgraduate scholarship will be published on the CSCO website, and the names of the personnel who have won the postgraduate scholarship will not be publicized.
Four. Fund reward
1, the scholarship fund has three first prizes, each with a reward of 10000 yuan;
Second prize 10, with a reward of 7000 yuan per person;
20 third prizes, each with a reward of 5000 yuan.
2. Scholarship Fund plans to support 100 master's, doctor's and postdoctoral students in oncology with financial difficulties. The amount of subsidy is determined according to the economic situation of the applicant, and the amount of subsidy is 5000 ~ 1 10,000 yuan/year/person.
Verb (abbreviation of verb) fund management
1. The fund is earmarked for special purposes, and no organization or individual may use it for other purposes.
2. Applicants funded by the Fund shall submit a research report to the Fund Review Committee when they graduate from school.
3. In principle, each person can only apply for scholarship fund or student fund once.
4. CSCO and Dalian Huali Jingang Pharmaceutical Co., Ltd. reserve the right to recover the funding according to law for those who have obtained the fund support by concealing the real situation or have committed serious violations of law and discipline during their school days.
6. "CSCO-Jingang Elemene Oncology Postgraduate Scholarship Fund Evaluation Committee" is composed of CSCO Society and Dalian Huali Jingang Pharmaceutical Co., Ltd., which can be adjusted in time.
Seven, this Ordinance shall come into force as of the date of promulgation.
China diamond elemene China traditional Chinese medicine cancer science fund
In order to promote the rapid development of TCM oncology in China and continuously improve the research level of clinical oncology, the Oncology Committee of China Association of Integrated Traditional Chinese and Western Medicine actively cooperated with Dalian Huali Jingang Pharmaceutical Co., Ltd. in 2009, and jointly established the "China TCM Oncology Subject Fund". China TCM Oncology Subject Fund belongs to non-.
The for-profit social welfare fund aims to encourage and support members of the oncology Committee of the Chinese Society of Integrated Traditional Chinese and Western Medicine to actively carry out research in the field of clinical oncology, promote unity and cooperation, strengthen academic exchanges, scientific cooperation and professional education at home and abroad, and accelerate the training of specialized personnel.
Its main funding scope:
Reward outstanding papers and scientific research achievements in oncology of traditional Chinese medicine in China;
Start-up funds for applied research and basic research projects of traditional Chinese medicine oncology;
Popularization of new knowledge and technology in TCM oncology.
CACA—— Adamantene Charity Activity for Caring for Patients
In order to make the series of China original invention patent anticancer drug "Jingang Elemene" produced by Dalian Huali Jingang Pharmaceutical Co., Ltd. better benefit cancer patients, show the concept of "charity marketing" of Dalian Huali Jingang Pharmaceutical Co., Ltd., offer a love to the society and contribute to building a harmonious doctor-patient relationship. China Anti-Cancer Association and Dalian Huali Jingang Pharmaceutical Co., Ltd. * * * jointly initiated and carried out the activities of offering love to cancer patients in poor families and giving away "Jingang Elemene" series of drugs for free, aiming at helping cancer patients complete treatment, improve their quality of life, prolong their survival time, pay attention to their survival interests and reduce their drug cost burden. In order to carry out this activity in an orderly and effective manner, these management measures are formulated.
1. The recipients are poor patients: urban and rural patients who enjoy the minimum living guarantee for urban (town) residents, the minimum living guarantee for rural farmers or the relief treatment for poor rural households and have not participated in the basic medical insurance.
2. The recipient's condition is that the patient received adamantine injection (or oral milk) treatment 1 course of treatment (60 capsules), and the symptoms improved obviously and the curative effect was good.
3. Screening of donated patients: The marketing academic specialist should communicate with the patient's attending doctor in advance. The attending doctor of the patient (who must be a member of China Anti-Cancer Association) and the cancer patient should apply for donation at the same time.
4. The marketing academic specialist should do a good job in investigating patients' situation, and fill in the Application Form for Giving Small Molecular Anti-tumor Plant Medicine Adamantene (see Annex 1) and the Application Form for Attending Doctors (who must be members of China Anti-Cancer Association) to Care for Cancer Patients (see Annex 2) when applying for charitable donations. And truthfully provide patients with the following materials: the minimum living difference guarantee card for non-agricultural population or the minimum living limit guarantee card for non-agricultural population issued by the office of the leading group of the minimum living guarantee line for urban residents; The Office of the Leading Group for Rural Social Assistance issued the "Assistance Card for Poor Rural Households"; County (city), the District People's government issued a unified "farmers minimum living guarantee Jinling evidence".
5. After the patient receives the donated "Jingang Elemene" medicine, the academic committee members should fill in the "China Anti-Cancer Association-Jingang Elemene Thousand Doctors Caring for Cancer Patients" (see Annex 3) in time, and return to Dalian Huali Jingang Pharmaceutical Co., Ltd. after being signed by the attending doctor and the patient himself.
6. In the process of using the donated adamantine to treat patients, academic experts should communicate with patients and attending doctors (who must be members of China Anti-Cancer Association) in time, follow up and know the drug use of patients in time.
7. Each patient only provides one course of treatment (60 capsules) for charitable donation. For patients with remarkable curative effect and typical cases, you can apply for drug donation to Dalian Huali Jingang Pharmaceutical Co., Ltd. again.
8. At the end of patients' medication, marketing academic experts and attending doctors shall submit a summary report on patients' use of donated drugs to the company. If there are any unused drugs, they should be returned to Dalian Huali Jingang Pharmaceutical Co., Ltd. in time.
9. Academic members and attending doctors of Dalian Huali Jingang Pharmaceutical Co., Ltd. shall not resort to deceit or seek personal gain in the name of drug donation in charitable activities. If it happens, after investigation, academic members should compensate Dalian Huali Jingang Pharmaceutical Co., Ltd. for the loss according to the value of drug donation and dismiss it.
10. Local offices of Dalian Huali Jingang Pharmaceutical Co., Ltd. can establish Jingang Elemene Love Rehabilitation Club with local branches of China Anti-Cancer Association and qualified hospitals. According to the actual situation in various places, we will carry out various caring activities that are beneficial to cancer patients, such as psychological rehabilitation lectures, dietary rehabilitation guidance, parties, giving away the Handbook of Psychological Rehabilitation for Cancer Patients and the Handbook of Dietary Rehabilitation for Cancer Patients. Help cancer patients improve their quality of life, prolong their survival time and let them enjoy the benefits of survival.
1 1, China Anti-Cancer Association-Jingang Elemene Thousand Doctors Caring for Cancer Patients' Public Welfare Activity was implemented from September to 20, 200811. After the expiration of the agreement, all parties can decide whether to extend the charity activities through consultation.
Clinical Research Fund of Elemene
1994 and 1996, China Anti-Cancer Association cooperated with Dalian Jingang Pharmaceutical Co., Ltd. twice to support the clinical research of elemene. Elemene is the first safe and effective anti-tumor drug verified by evidence-based medicine in China. Previous studies have confirmed that elemene has a good effect on the treatment of malignant tumors such as lung cancer, gastric cancer, breast cancer, liver cancer, brain tumor, esophageal cancer, nasopharyngeal carcinoma, leukemia, gynecological tumor, bone metastasis and cancerous pleural effusion, which can relieve cancer pain and improve the body's immunity. But the data is scattered and the number of cases is small. In 2004, China Anti-Cancer Association cooperated with Dalian Huali Jingang Pharmaceutical Co., Ltd. again to carry out the long-term effect evaluation project of large-scale evidence-based medicine for elemene injection, oral emulsion and conventional radiotherapy and chemotherapy. This project is a multi-center, multi-disease and multi-program evidence-based medicine research. The research results will be announced at the 6th National Conference on Oncology on 20 10, and the individuals and units that have made outstanding contributions in this project will be commended.